SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

S&P 100 NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

Biogen Idec Inc: Click to view the issuer\'s details

Last update : 21/08/2018  >View issuer details

2019.06.12 | 01:05 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019 - HTML (w)

2019.06.07 | 11:41 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million - HTML (w)

2019.05.30 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis - HTML (w)

2019.05.20 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation - HTML (w)

2019.05.15 | 01:02 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy - HTML (w)

2019.05.07 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS - HTML (w)

2019.05.06 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen) - HTML (w)

2019.05.01 | 22:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) - HTML (w)

2019.05.01 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases - HTML (w)

2019.04.30 | 13:33 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy - HTML (w)

2019.04.29 | 13:30 | Permanent Information Releases / Appointments

English version HTML (w) Mail

puce Biogen Announces Three New Nominees for Election to Board of Directors - HTML (w)

2019.04.24 | Periodic information / 1st Quarter Information

English version PDF Mail

puce Biogen Idec Inc : First quarter 2019 financial results - PDF (457Kb)

2019.04.12 | 13:30 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference - HTML (w)

2019.03.21 | 12:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease - HTML (w)

2019.03.12 | 08:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 / Doc nb : 62